Xiangyu Zhao
Peking University People's Hospital · PEKING UNICERSITY PEOPLE'S HOSPITAL
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Xiangyu Zhao as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:53 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07925554 · Interferon-α Maintenance in Favorable-Risk AMLPeking University People's Hospital · recruiting · AML (Acute Myeloid Leukemia) · study chair
- Early Ph1NCT07617740 · IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)Peking University People's Hospital · recruiting · REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS · principal investigator
- Ph1NCT07617285 · Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AMLPeking University People's Hospital · recruiting · AML, Refractory/Relapse Acute Myeloid Leukemia · principal investigator
- Ph2NCT07244380 · Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.Hebei Senlang Biotechnology Inc., Ltd. · not yet recruiting · T Lymphoblastic Leukemia/Lymphoma · principal investigator
- Ph1NCT06209671 · INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic LeukemiaBeijing Immunochina Medical Science & Technology Co., Ltd. · unknown · Leukemia, B-cell · principal investigator
- Ph1/Ph2NCT06075927 · Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCTPeking University People's Hospital · unknown · CMV Infection, EBV Infection, Stem Cell Transplant · study chair
- Ph1NCT05548088 · LILRB4 STAR-T Cells in the Treatment of R/R AML/CMMLPeking University People's Hospital · completed · Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:53 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity.Ann Hematol · 201382 citationsRCR 2.6
- Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo.Eur J Immunol · 202043 citationsRCR 1.7
- 26 citationsRCR 1.3
- 17 citationsRCR 0.6
- Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens.J Transl Med · 201816 citationsRCR 0.6
- Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.J Transl Med · 201915 citationsRCR 0.5
- Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.Ann Hematol · 202113 citationsRCR 0.9
- 7 citationsRCR 0.5
- Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial.J Immunother Cancer · 20245 citationsRCR 0.5
- [Clinical Curative Efficacy of Lenalidomide Combined with Chemotherapy for Acute Leukemia and Its Impact on VEGF].Zhongguo Shi Yan Xue Ye Xue Za Zhi · 20164 citationsRCR 0.1